Author

J. Wilson-Sanchez

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:mouse· 2 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Approach:experimental assay· 1 Research Focus:host-pathogen & immune response· 1 Assay:imaging· 1 Approach:statistical model· 1

Frequent Co-Authors

M. Koti· 2 shared N. Shakfa· 2 shared A. Asante· 1 shared A. Hamade· 1 shared A. O. Cudmore· 1 shared A. Tone· 1 shared B. C. Vanderhyden· 1 shared B. J. Laight· 1 shared

Activity by Year

2022-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 29 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

M. Koti

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Comparative analysis of syngeneic mouse models of high-grade serous ovarian cancer

D. P. Cook, K. J. Galpin, G. M. Rodriguez, N. Shakfa, J. Wilson-Sanchez, M. Pereira, K. Matuszewska, J. Haagsma, H. Murshed, A. O. Cudmore, E. MacDonald, A. Tone, T. G. Shepherd, J. J. Petrik, M. Koti, B. C. Vanderhyden

The paper compares syngeneic mouse models of high-grade serous ovarian cancer to identify differences in signaling, metabolic, and functional properties, as well as tumor microenvironment variability.

bioRxiv · Mar 9, 2023Cancer Biology

PTEN and BRCA1 tumor suppressor loss associated tumor immune microenvironment exhibits differential response to therapeutic STING pathway activation in a murine model of ovarian cancer

N. Shakfa, D. Li, G. Conseil, E. D. Lightbody, J. Wilson-Sanchez, A. Hamade, S. Chenard, B. J. Laight, A. Asante, K. Tyryshkin, M. Köbel, M. Koti

This study examines how PTEN and BRCA1 loss in ovarian cancer affects tumor immune microenvironment response to STING pathway activation, showing improved survival in PTEN-deficient tumors with STING therapy.

bioRxiv · Jun 27, 2022 · PreprintImmunology